VALN · Valneva SE
AI read · Good for VALN
The AI's read
The results give Valneva evidence that S4V2 may protect people from shigellosis. The infant study also found a favorable safety profile and increased antibodies against all 4 targeted types.
Valneva Evaluates Next Steps for Bacterial Infection Vaccine Following Successful Phase 2 Studies
Good for VALN
Valneva reported vaccine results that support S4V2’s potential to prevent shigellosis, with a favorable safety profile in infants. Dose and schedule work remains, but the reported results support further development.
Get alerts for VALN
Follow Valneva SE (VALN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VALNFree on the App Store and Google Play, or on the web.